Board of Directors


David Chiswell, Ph.D.

Chairman of the Board, Albireo”; Chief Executive Officer, Kymab

After a career as a research scientist in both the United Kingdom and the United States and nine years working in scientific management at Amersham International, David Chiswell co-founded Cambridge Antibody Technology (CAT) and served as its CEO for several years. In addition to Albireo, Dr. Chiswell is currently CEO of Kymab Ltd.

He was previously chairman of the UK’s BioIndustry Association (BIA) and remains on its board. In 2006, Dr. Chiswell was awarded the OBE by HM Queen for services to the biotechnology industry.


Julia R. Brown


Julia Brown has held a variety of executive positions over her 40-year career in the pharmaceutical industry, including as Executive Vice President and Advisor to the CEO of Amylin Pharmaceuticals, Inc. and Executive Vice President of Dura Pharmaceuticals, Inc. Previously, she spent over 25 years with Eli Lilly and Company in progressively senior roles, including Vice President of IVAC Corporation and General Manager of its Vital Signs Division and Vice President of Worldwide Marketing for Hybritech. Julia is an experienced director, having served previously on the boards of directors of eight drug development companies and as chairperson of the Corporate Directors Forum. She is chair emerita of the UC San Diego Foundation and a member of the board of two industry associations. Julia earned her undergraduate degree from Louisiana Tech University and a Master’s degree from Harvard.


Michael Gutch, Ph.D.

”Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Mike Gutch is currently Chief Business Officer and Chief Financial Officer at Entasis Therapeutics. Prior to Entasis, he served as an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for mergers and acquisitions, divestments, and strategic equity investments. Previously, Dr. Gutch had experience as both a corporate and private venture capital investor as a Managing Director of MedImmune Ventures, a Director with H.I.G. BioVentures, and a Principal with Lilly Ventures, the corporate venture capital arm of Eli Lilly & Company. While at Eli Lilly, Dr. Gutch was also in the Corporate Financing and Investment Banking group, where he focused on mergers and acquisitions and licensing transactions.

Dr. Gutch earned his Ph.D. in Cellular and Molecular Pathology from the State University of New York at Stony Brook and was a post-doctoral research fellow at both UCSF and the Cold Spring Harbor Laboratories. He earned his M.B.A. in finance from Indiana University. Mike also serves as a Board Director of PhaseBio Pharmaceuticals, Entasis Therapeutics, and is a member of the Board of Directors for Southeast BIO, a member of the Johns Hopkins Alliance for Science & Technology Development, and the Emory University New Venture Advisory Board.

Heather Preston of TPG

Heather Preston, M.D.

Partner & Managing Director, TPG Biotech

Heather Preston is Managing Director at TPG Biotech. Prior to joining TPG Biotech in 2005, Dr. Preston worked in investment banking at JP Morgan Partners, served as an Entrepreneur-in-Residence with New Enterprise Associates, and was a leader of the pharmaceutical and medical products consulting practice at McKinsey & Co. She has an undergraduate degree in biochemistry from the University of London, a medical degree from the University of Oxford, and a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University.

She completed her training in Internal Medicine at the Massachusetts General Hospital and then sub-specialized in Gastroenterology and Hepatology at University of California, San Francisco. During her academic career, Dr. Preston was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-Doctoral Fellowship Award. In addition to Albireo, Dr. Preston serves on the Board of Directors of Alder Biotherapeutics (NASDAQ: ALDR) and numerous private companies.


Davey S. Scoon


Davey Scoon’s business career has included senior executive positions in finance and administration at Tom’s of Maine, Inc., Sunlife Financial U.S. and Liberty Funds Group of Boston (formerly Colonial Management), as well as serving as a CPA with Price Waterhouse & Company. He is currently chairman of the Board of Trustees for Allianz Global Investors and a director and chairman of the Audit Committee of AMAG Pharmaceuticals, Inc. Among other roles, he previously served as non-executive chairman of Tufts Health Plan. Davey is also an adjunct professor teaching accounting at the University of Wisconsin-Madison. He earned an MBA from Harvard Business School and a BBA in Business Administration from the University of Wisconsin.


Denise Scots-Knight, Ph.D.

”CEO and Co-Founder, Mereo BioPharma

Denise Scots-Knight is CEO and co-Founder of Mereo BioPharma. She is also Managing Partner for Phase4 Partners (formerly known as Phase4 Ventures), where she has been responsible for its investment activities since 1999. Prior to joining Phase4, Dr. Scots-Knight was an investment manager at Rothschild Asset Management and also held senior management positions in R&D and strategic consulting.

In addition to Albireo, she serves on the Board of Directors of Oncomed Pharmaceuticals. Dr. Scots-Knight holds a Ph.D. and B.Sc. (Hons) from Birmingham University and was a Fulbright Scholar at the University of California, Berkeley.


Ron Cooper

”President and Chief Executive Officer

Ron Cooper, Albireo’s first President and CEO, is a global P&L leader with a track record of growing businesses, brands and organizations in the U.S. and Europe. For over 25 years, Ron worked in five different countries and held positions of increasing responsibility in sales, marketing and general management with Bristol-Myers Squibb, culminating in his role as President of Europe where he was responsible for over 30 countries with sales exceeding $4.5 billion.

While at BMS, Ron played a leadership role in several product successes, including Abilify®, Avapro®, Atripla®, Eliquis®, Orencia®, Pravachol®, Plavix®, Reyataz® Sustiva® Sprycel® and Yervoy®. Ron has successfully completed more than a dozen business development deals, including the creation of the first single tablet HIV/AIDS regimen partnership. He is a graduate of St. Francis Xavier University in Canada.

Albireo Homepage